The Drug Discovery World Podcast

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dimitrios Goundis, CEO of Kither Biotech. Kither is a Phase I, soon to be Phase II, Italian biotech focused on respiratory diseases such as cystic fibrosis. This episode explores how emerging biotech strategies are advancing treatments for respiratory diseases like cystic fibrosis, with a focus on targeted drug delivery, clinical trial progression, and the evolving biotech landscape in Europe. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

The latest episode of the DDW Highlights podcast is now available. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the American Association of Cancer Research (AACR) Annual Meeting taking place from 25-30 April, the DDW news desk has been inundated with the latest advances in cancer drug discovery, so here are a few highlights. Check out our round-up for the event for more updates. You can listen here, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “An overview on the impact of synthetic biology”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Synthetic biology: Impacting drug discovery” and “Synthetic biology: Innovating in drug discovery” In the first article, Mark Kotter, Founder and CEO of bit.bio, talks with Reece Armstrong about different approaches to synthetic biology and its applications in programming stem cells into mature, functional human cells for drug discovery and the creation of next generation. In the second article, Reece Armstrong examines recent activity within the synthetic biology sector and highlights some of the key advancements and innovation.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug to market, having announced positive topline results from a Phase III trial, this week our news highlights focus on clinical studies. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “The start-up disrupting the field of women’s reproductive health” and “India: Why is the country ramping up drug discovery research?” Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer’s disease. The focus of the trial is to test Cognition Therapeutics’ experimental drug, CT1812 for patients with dementia with Lewy Bodies and dry age-related macular degeneration. In the first article, Reece Armstrong speaks to Lisa Ricciardi, CEO of Cognition Therapeutics, to learn about what the company hopes to achieve with CT1812. In the second article, DDW’s Diana Spencer speaks to Alok Javali, CSO of dawn-bio, a new addition to BioInnovation Institute’s (BII) Venture Lab acceleration programme, about the lack of innovation in women’s reproductive health and the company’s plans to fill the vacuum. In the third article, I take a deeper look into why India is ramping up drug discovery research, and explores the country’s innovation hubs of interest.

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In a week of financial uncertainty for the industry, our round-up focuses on the power of partnership to accelerate drug discovery, from the prevention of respiratory infections, to mapping gene activity in inflammatory bowel disease. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Accelerating biotherapy and personalised medicine with long DNA” and “The microbiome in precision medicine”. In the first article, Matt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development. In the second article, Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio, provide an industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development.

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Sitting down with… Neil Dhawan”, “Meet the researcher: Giusy Di Conza, iOnctura” and “From the Top: Adele Hannigan, Antibody Analytics”. In the first article, Reece Armstrong speaks to Neil Dhawan, the Co-founder and CEO of Totus Medicines about the company’s approach to drug discovery using fundamental technologies in chemistry, biology and artificial intelligence (AI). In the second article, Megan Thomas looked at a day in the life of Giusy Di Conza, Head of Research at iOnctura. In the third article, Megan Thomas shines a spotlight on Adele Hannigan, CBO for Antibody Analytics, which has since been rebranded as RoukenBio.

This is the latest episode of the free DDW narrated podcast, titled “Innovation enabled by new drug discovery technologies”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases will benefit from therapeutic antibody development?” In the first article, Katie Abouzahr is the Vice President, Autoantibody Portfolio and Maternal Fetal Disease Area Leader at the Janssen Pharmaceutical Companies of Johnson & Johnson. She speaks with Megan Thomas about the future for Janssen’s investigational medicine nipocalimab and antibody therapeutics at large. In the second article, DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies.

The latest episode of the DDW Highlights podcast is now available to listen. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Weight loss drugs have been making the news this week. As we come to the end of Women’s History Month, two of the covered studies focus on women’s health, specifically the role of weight loss drugs in treating endometriosis and why women have worse side effects from these therapeutics.  You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.